Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/31920| Title: | Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. | Austin Authors: | Watts, Justin M;Baer, Maria R;Yang, Jay;Prebet, Thomas;Lee, Sangmin;Schiller, Gary J;Dinner, Shira N;Pigneux, Arnaud;Montesinos, Pau;Wang, Eunice S;Seiter, Karen P;Wei, Andrew H;De Botton, Stephane;Arnan, Montserrat;Donnellan, Will;Schwarer, Anthony P ;Récher, Christian;Jonas, Brian A;Ferrell, P Brent;Marzac, Christophe;Kelly, Patrick;Sweeney, Jennifer;Forsyth, Sanjeev;Guichard, Sylvie M;Brevard, Julie;Henrick, Patrick;Mohamed, Hesham;Cortes, Jorge E | Affiliation: | University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA. University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA. Karmanos Cancer Institute, Detroit, MI, USA. Department of Hematology, Yale University, New Haven, CT, USA. Department of Hematology and Oncology, Weill Cornell Medicine, New York, NY, USA. David Geffen School of Medicine at University of California, Los Angeles, CA, USA. Department of Hematology and Oncology, Northwestern University, Chicago, IL, USA. Centre Hospitalier Universitaire Bordeaux, Bordeaux, France. Hospital Universitari i Politècnic La Fe, Valencia, Spain. Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. New York Medical College, New York, NY, USA. The Alfred Hospital and Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia. Institut Gustave-Roussy, Villejuif, France. Institut Català d'Oncologia-Hospital Duran i Reynals, IDIBELL, Hospitalet Llobregat, Barcelona, Spain. Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN, USA. Eastern Health Monash University Clinical School and Austin Hospital, Melbourne, Australia. Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France. University of California, Davis Comprehensive Cancer Center, Sacramento, CA, USA. Vanderbilt University, Nashville, TN, USA. Institut Gustave-Roussy, Villejuif, France. Austin Health Forma Therapeutics, Watertown, MA, USA. Georgia Cancer Center, Augusta, GA, USA. |
Issue Date: | Jan-2023 | Date: | 2022 | Publication information: | The Lancet. Haematology 2023; 10(1) | Abstract: | Olutasidenib (FT-2102) is a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aims for phase 1 of this phase 1/2 study were to assess the safety, pharmacokinetics, pharmacodynamics, and clinical activity of olutasidenib, as monotherapy or in combination with azacitidine, in patients with acute myeloid leukaemia or myelodysplastic syndrome, harbouring mutant IDH1. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/31920 | DOI: | 10.1016/S2352-3026(22)00292-7 | ORCID: | Journal: | The Lancet. Haematology | Start page: | e46 | End page: | e58 | PubMed URL: | 36370742 | ISSN: | 2352-3026 | Type: | Journal Article | Subjects: | Azacitidine/adverse effects Myelodysplastic Syndromes/drug therapy Myelodysplastic Syndromes/genetics Leukemia, Myeloid, Acute/drug therapy Leukemia, Myeloid, Acute/genetics Antineoplastic Combined Chemotherapy Protocols/adverse effects Thrombocytopenia/chemically induced Thrombocytopenia/drug therapy Febrile Neutropenia/drug therapy Isocitrate Dehydrogenase/genetics |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.